Endocrine Consequences of Long-Term Intrathecal Administration of Opioids

Author:

Abs Roger1,Verhelst Johan12,Maeyaert Jan3,Van Buyten Jean-Pierre4,Opsomer Frank5,Adriaensen Hugo6,Verlooy Jan72,Van Havenbergh Tony2,Smet Mike7,Van Acker Kristien1

Affiliation:

1. Department of Endocrinology, University Hospital Antwerp (R.A., K.V.A.), B-2650 Edegem, Belgium

2. Department of Neurosurgery, University Hospital Antwerp (J.V., T.V.H.), B-2650 Edegem, Belgium

3. Department of Anesthesiology, Heilig Hart Hospital Eeklo (J.M.), B-2650 Edegem, Belgium

4. Maria Middelares Hospital St. Niklaas (J.-P.V.B.), B-2650 Edegem, Belgium

5. Middelheim Hospital Antwerp (F.O.), B-2650 Edegem, Belgium

6. University Hospital Antwerp (H.A.), B-2650 Edegem, Belgium

7. Middelheim Hospital Antwerp (J.V., M.S.), B-2650 Edegem, Belgium

Abstract

Intrathecal administration of opioids is a very efficient tool in the long-term control of intractable nonmalignant pain. However, despite the well known role of opioids in endocrine regulation, few data are available about possible effects on hypothalamic-pituitary function during this treatment. Seventy-three patients (29 men and 44 women; mean age, 49.2 ± 11.7 yr) receiving opioids intrathecally for nonmalignant pain were enrolled for extensive endocrine investigation. At the time of hormonal determination, the mean duration of opioid treatment was 26.6 ± 16.3 months; the mean daily dose of morphine was 4.8 ± 3.2 mg. The control group consisted of 20 patients (11 men and 9 women; mean age, 54.2 ± 14.0 yr) with a comparable pain syndrome but not treated with opioids. Decreased libido or impotency was present in 23 of 24 men receiving opioids. The serum testosterone level was below 9 nmol/L in 25 of 29 men and was significantly lower than that in the control group (P < 0.001). The free androgen index was below normal in 18 of 29 men and was significantly lower than that in the control group (P < 0.001). The serum LH level was less than 2 U/L in 20 of 29 men and was significantly lower than that in the control group (P < 0.001). Serum FSH was comparable in both groups. Decreased libido was present in 22 of 32 women receiving opioids. All 21 premenopausal females developed either amenorrhea or an irregular menstrual cycle, with ovulation in only 1. Serum LH, estradiol, and progesterone levels were lower in the opioid group. In all 18 postmenopausal females significantly decreased serum LH (P < 0.001) and FSH (P = 0.012) levels were found. The 24-h urinary free cortisol excretion was below 20 μg/day in 14 of 71 opioid patients and was significantly lower than that in the control group (P = 0.003). The peak cortisol response to insulin-induced hypoglycemia was below 180 μg/L in 9 of 61 opioid patients and was significantly lower than that in the nonopioid group (P = 0.002). The insulin-like growth factor I sd score was below −2 sd in 12 of 73 opioid patients and was significantly lower than that in the control group (P = 0.002). The peak GH response to hypoglycemia was below 3 μg/L in 9 of 62 subjects and was significantly lower than that in the control group (P = 0.010). Thyroid function tests and PRL levels were considered normal. No metabolic disturbances were recorded, apart from significantly decreased high density lipoprotein cholesterol levels (P = 0.041) and elevated total/high density lipoprotein cholesterol ratio (P = 0.008) in the opioid group compared to the control group. Supplementation with gonadal steroids improved sexual function in most patients. In conclusion, of all patients receiving intrathecal opioids, the large majority of men and all women developed hypogonadotropic hypogonadism, about 15% developed central hypocorticism, and about 15% developed GH deficiency. These findings suggest that further investigations are required to determine the need for systematic endocrine work-up in these patients and the necessity for substitutive therapy.

Publisher

The Endocrine Society

Subject

Biochemistry, medical,Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Reference32 articles.

1. Adverse effects of systemic opioid analgesics.;Schug;Drug Safety,1992

2. The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society.;Haddox;Clin J Pain,1997

3. Role of epidural and intrathecal narcotics and peptides in the management of cancer pain.;Med Clin North Am,1987

4. Clinical realities and economic considerations: special therapeutic issues in intrathecal therapy–tolerance and addiction;Portenoy;J Pain Symptom Manage.,1997

5. Clinical realities and economic considerations: economics of intrathecal therapy;Hassenbush;J Pain Symptom Manage.,1997

Cited by 254 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3